Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies

Ferenc Magyari1,2 · László Imre Pinczés1,2 · Edit Páyer1,2 · Katalin Farkas1,2 · Szilvia Ujfalusi3 · Ágnes Diószegi3 · Máté Sik4 · Zsófia Simon1 · Gergely Nagy5 · Zsuzsanna Hevessy6 · Béla Nagy Jr5 · Árpád Illés1,2

Received: 2 February 2022 / Accepted: 6 July 2022 / Published online: 14 July 2022
© The Author(s) 2022

Abstract
Patients with hematological malignancies (HMs) are at a higher risk of developing severe form and protracted course of COVID-19 disease. We investigated whether the combination of viral replication inhibition with remdesivir and administration of anti-SARS-CoV-2 immunoglobulins with convalescent plasma (CP) therapy might be sufficient to treat B-cell-depleted patients with COVID-19. We enrolled 20 consecutive patients with various HMs with profound B-cell lymphopenia and COVID-19 pneumonia between December 2020 and May 2021. All patients demonstrated undetectable baseline anti-SARS-CoV-2 immunoglobulin levels before CP. Each patient received at least a complete course of remdesivir and at least one unit of CP. Previous anti-CD20 therapy resulted in a more prolonged SARS-CoV-2 PCR positivity compared to other causes of B-cell lymphopenia (p = 0.004). Timing of CP therapy showed a significant impact on the clinical outcome. Simultaneous use of remdesivir and CP reduced time period for oxygen weaning after diagnosis (p = 0.017), length of hospital stay (p = 0.007), and PCR positivity (p = 0.012) compared to patients who received remdesivir and CP consecutively. In addition, time from the diagnosis to CP therapy affected the length of oxygen dependency (p < 0.001) and hospital stay (p < 0.0001). In those cases where there were at least 10 days from the diagnosis to plasma administration, oxygen dependency was prolonged vs. patients with shorter interval (p = 0.006). In conclusion, the combination of inhibition of viral replication with passive immunization was proved to be efficient and safe. Our results suggest the clear benefit of early, combined administration of remdesivir and CP to avoid protracted COVID-19 disease among patients with HMs and B-cell lymphopenia.

Keywords COVID-19 · SARS-CoV-2 · Convalescent plasma treatment · Remdesivir · Hematological malignancies · Immunodeficiency

Introduction
The newly identified coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic characterized by severe atypical pneumonia in 15–20% of all cases and a rapid human-to-human transmission.

Immunocompromised patients, especially patients with hematological malignancies (HMs), are at a high risk of developing a severe form and protracted course of COVID-19 [1–3]. HMs are associated with defects in humoral and cellular immunity, while treatment often exacerbates these immune deficiencies and can lead to prolonged B-cell depletion, contributing to unfavorable COVID-19 outcomes [4].

Remdesivir, an inhibitor of the viral RNA-dependent RNA polymerase, was identified early as a promising therapeutic candidate for COVID-19 because of its ability to inhibit SARS-CoV-2 [5]. However, antiviral monotherapy appears to be an insufficient treatment option in the absence of humoral immunity [6–8]. Convalescent plasma (CP) isolated from patients who have recovered from COVID-19 infection contains high levels of antibodies against SARS-CoV-2 that may be suitable for passive...
immunization of recipients for both prophylactic and therapeutic purposes [9]. The effectiveness of CP transfusion in other infectious diseases has been demonstrated over the past decades [10, 11]. The use of CP in COVID-19 patients has shown conflicting results and only a limited amount of data is available on its administration in B-cell-depleted patients [12–14]. The use of CP has not been specifically assessed in clinical trials in the population of B-cell depleted patients. To avoid the development of protracted COVID-19 disease, it is of paramount importance in HM patients. In addition to the cumulative infectious complications and deterioration in quality of life, the mortality of patients due to the underlying disease is a major concern. Dose reduction or postponement of treatment due to COVID-19 can lead to reduced overall- and progression-free survival of HM patients with active disease.

In this study, we hypothesize that the combination of exogenous anti-SARS-CoV-2 antibodies and inhibition of viral replication may be sufficient to effectively treat COVID-19 patients with different HMs. Therefore, we investigated the clinical and laboratory response to the combination of remdesivir and CP in a considerably large cohort of B-cell-depleted subjects.

Methods

Subjects

The observational, single-center study was conducted in the COVID-19 Epidemiological Care Centre, University of Debrecen, Hungary, between December 2020 and July 2021. Diagnosis of COVID-19 was based on a positive PCR test result for SARS-CoV-2 infection from a nasopharyngeal swab. Evaluated patients demonstrated a profound B-cell lymphopenia based on flow cytometry analysis of peripheral blood lymphocyte subpopulations. They showed undetectable baseline anti-SARS-CoV-2 immunoglobulin (Ig) levels before CP transfusion according to the results of automated anti-SARS-CoV-2 nucleocapsid- and Spike protein1-receptor binding domain (S1-RBD)-specific total Ig tests. Each patient received a complete course of remdesivir and at least one unit (200 mL) of AB0 compatible CP during their treatment for COVID-19. Post-transfusion anti-SARS-CoV-2 Ig levels were measured 12 h after CP administration and regularly thereafter. Our research was undertaken in accordance with relevant guidelines and regulations. All patients involved signed an informed consent form. The severity of COVID-19 was evaluated according to the World Health Organization (WHO) Clinical Progression Scale [15].

Data sources and definitions

Data were extracted from patients’ medical charts and were obtained on their demographics, complete medical history, comorbidities, detailed chemotherapy use, and malignancy status at admission. COVID-19-related data included time of symptom onset, diagnosis, laboratory and imaging results, specific medications, and oxygen supply. Remdesivir and CP therapy were considered simultaneous if CP therapy was initiated before completing the first cycle of remdesivir. Length of hospital stay was defined as the time period between the first admission for COVID-19 symptoms and final discharge or death.

Treatment protocols

Remdesivir treatment was administered at a maintenance dose of 100 mg per day following a saturating dose of 200 mg intravenously. A treatment cycle consisted of 5–15 days. A patient was allowed a maximum of 2 treatment cycles. Absolute contraindications to remdesivir treatment were severe renal failure (GFR-EPI less than 30 mL/min/1.73 m²) and acute liver failure (Child–Pugh Class C).

Plasma donors who recovered from COVID-19 infection signed a consent form for CP donation. The age of eligibility for donation was generally defined as between 18 and 60 years. Eligibility was restricted to those who were negative for human immunodeficiency virus (HIV), hepatitis B, hepatitis C, and syphilis. Donors were free of any symptoms and complaints for at least 2 weeks at pre-screening, were negative for SARS-CoV-2 PCR test on a nasopharyngeal swab, and had detectable serum anti-SARS-CoV-2 IgG level. The donors underwent plasmapheresis providing 600 mL of plasma collected over approximately 1 h. The final product was irradiated and stored by the Hungarian National Blood Transfusion Service. The preparations were dispensed in 3 × 200 mL fractions. CP was derived from patients cured of COVID-19 in the same wave (alpha and beta mutant, 2nd and 3rd wave, from November 2020 to June 2021). Via the monitoring protocol, antibody measurements were performed immediately after CP administration, and at 12, 48, 72, and 138 h after CP infusion.

Laboratory analysis

Total Ig levels against SARS-CoV-2 nucleocapsid and S1-RBD were measured by automated immunoassays (Elecys® Anti-SARS-CoV-2 and Anti-SARS-CoV-2 S
tests, Roche Diagnostics, Mannheim, Germany) at the cut-off value of 1.0 (cut-off index, COI) and 0.8 U/mL titer, respectively, according to the instructions of the manufacturer.

B-cell depletion was defined by flow cytometry before and under CP plus remdesivir therapy to analyze whether peripheral CD19 + B cells were ≤80/μL or percentage among total lymphocytes were ≤5%. White blood cells were stained by anti-CD19-PE and anti-CD3-APC (Becton Dickinson, Franklin Lakes, NJ, USA). In case of anti-CD20 therapy, 500,000 dual-color–labeled leukocytes were acquired on a FASCan do II flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA), while 100,000 events were analyzed in the follow-up samples. Results were expressed as the percentage of lymphocytes.

Statistical analysis

Categorical variables are given as their frequencies and percentages, while continuous variables with medians and ranges. Continuous variables were evaluated using the Mann–Whitney U test or t-test based on the normality of the data. The Shapiro–Wilk test was used for evaluation of data normality. Simple linear regression was used to test if the time interval from COVID-19 diagnosis to CP therapy or post-transfusion anti-SARS-CoV-2 Ig titers predicted the outcome. The level of statistical significance was considered at \( p < 0.05 \). Statistical analyses were performed using SPSS 26.0 (IBM Corp., Armonk, NY, USA).

Results

A total of 20 B-cell depleted hematological patients were included in our study (Table 1, Online Resource 1). The median age at COVID-19 diagnosis was 56 years (range 27–76) with a male predominance (male to female ratio 1.8). All patients had biopsy-proven HM with the majority suffering from an active disease. Sixteen (80%) patients had B-cell origin disorder; only a minority of them was heavily pretreated. Thirteen (65%) subjects received anti-CD20 therapy within the last 2 years, while only two (10%) patients were treatment-naive at the time of COVID-19 diagnosis. None of the vaccinated patients had detectable baseline anti-SARS-CoV-2 Ig levels at the time of diagnosis.

Most patients were diagnosed and admitted early with COVID-19, with a median of 3.5 days after the onset of symptoms. Most of them were administered antiviral treatment immediately, within 24 h after hospital admission. Eighteen (90%) patients experienced a moderate COVID-19 disease course according to the WHO Severity Score (4–5). Median days of remdesivir treatment and median units of CP therapy were 12.5 (8–30) and 4 (1–15), respectively.

Table 1 Patient characteristics

| Characteristics                                      | Data          |
|-----------------------------------------------------|---------------|
| Age, median, years (range)                           | 56 (27–76)    |
| Male/female, n                                      | 13/7          |
| Hematological malignancy, n (%)                     |               |
| Acute lymphoid leukemia                              | 1 (5)         |
| Acute myeloid leukemia                               | 2 (10)        |
| Mixed phenotype acute leukemia                       | 1 (5)         |
| Chronic lymphoid leukemia                            | 4 (20)        |
| Diffuse large B-cell lymphoma                        | 4 (20)        |
| Follicular lymphoma                                  | 2 (10)        |
| Mantle cell lymphoma                                 | 3 (15)        |
| Splenic marginal zone lymphoma                       | 1 (5)         |
| Myelofibrosis                                        | 1 (5)         |
| Multiple myeloma                                     | 1 (5)         |
| Disease status, n (%)                                |               |
| Complete remission                                   | 9 (45)        |
| Partial remission                                    | 3 (15)        |
| Progressive disease                                  | 8 (40)        |
| Previous lines of therapy, median, n (range)         | 1 (0–5)       |
| Previous treatment with anti-CD20 therapy, n (%)     |               |
| Rituximab                                            | 10 (50)       |
| Obinutuzumab                                         | 3 (15)        |
| None                                                 | 7 (35)        |
| Last chemotherapy, n (%)                             |               |
| Anti-CD20 + chemotherapy                             | 3 (15)        |
| Anti-CD20 maintenance                                 | 5 (25)        |
| Classical chemotherapy                               | 4 (20)        |
| Small molecule                                       | 4 (20)        |
| Treatment naive                                      | 2 (10)        |
| Other                                                | 2 (10)        |
| Hemopoietic stem cell transplantation, n (%)         |               |
| Autologous                                           | 5 (25)        |
| Allogenic                                            | 1 (5)         |
| None                                                 | 14 (70)       |
| COVID-19 severity score (WHO), n (%)                 |               |
| 4                                                    | 8 (40)        |
| 5                                                    | 10 (50)       |
| 6–7                                                  | 0             |
| 8–9                                                  | 2 (10)        |
| COVID-19 specific treatments, n (%)                  |               |
| Favipiravir                                          | 9 (45)        |
| Dexamethasone                                        | 20 (100)      |
| Tocilizumab                                          | 0             |
| Bamlanivimab                                         | 5 (25)        |
| Days of remdesivir therapy                           |               |
| All patients, median, n (range)                      | 12.5 (8–30)   |
| Short course (8–10 days), n (%)                      | 4 (20)        |
| Intermediate course (11–20 days), n (%)              | 14 (70)       |
| Long course (21–30 days), n (%)                      | 2 (10)        |
| Convalescent plasma units, median, n (range)         | 4 (1–15)      |
| Simultaneous use of remdesivir and CP, n (%)         | 17 (85)       |
Remdesivir and CP were administered simultaneously in case of 17 patients. Five patients (25%) received a repeated treatment cycle of remdesivir. Apart from dexamethasone, CP, and remdesivir, COVID-19-specific treatments were administered after initial therapy with an intent to accelerate viral clearance. Five patients received bamlanivimab treatment after clinical resolution of COVID-19 symptoms, but persisting PCR positivity, 24–98 days after initial diagnosis.

Anti-CD20 therapy prior to COVID-19 diagnosis resulted in a prolonged PCR positivity compared to non-recipients (p = 0.004) (Fig. 1a). The severity of B-cell depletion, disease status, other treatment modalities, and demographic parameters did not affect the outcome of these patients. We analyzed data on T-cell counts (CD3+, CD4+, CD8+, CD56+/CD3−, CD56+/CD3− cell populations) at COVID-19 diagnosis but did not find noteworthy correlation with any of the observed outcomes in this study.

Three patients (with follicular lymphoma, diffuse large B-cell lymphoma transformed from follicular lymphoma, and acute myeloid leukemia) received remdesivir monotherapy before CP and showed a temporary clinical improvement but relapsed within a few days after completion of the antiviral treatment. However, all patients simultaneously receiving a combination of remdesivir and CP experienced a fast and sustained resolution of symptoms. The median length of hospital stay was 22.5 days (10–83), while patients receiving remdesivir and CP simultaneously were discharged earlier compared to patients treated consecutively (p = 0.007) (Fig. 1b). Simultaneously treated patients also experienced a remarkably reduced time to PCR negativity (p = 0.012) and loss of oxygen demand (p = 0.017), while there was no difference in the length of oxygen therapy after initiation of CP therapy (Fig. 1c–e). Furthermore, early CP administration led to an early cessation of oxygen demand, compared to patients receiving CP at least 10 days after COVID-19 diagnosis (p = 0.006) (Fig. 1f). With linear regression analysis, time from diagnosis to CP therapy showed a statistically significant impact on the length of oxygen dependency (R² = 0.768, F = 33.1, p < 0.001) and on the length of hospital stay (R² = 0.621, F = 29.4, p < 0.0001) (Fig. 2a and b). This correlation was even more pronounced in patients receiving anti-CD20 treatment (R² = 0.936, F = 87.6, p < 0.0001 and R² = 0.771, F = 36.9, p < 0.0001, respectively) (Fig. 2c and d).

All patients presented detectable anti-SARS-CoV-2 IgG 12 h after the first CP transfusion. Anti-SARS-CoV-2 nucleocapsid- and S1-RBD-specific total Ig levels were median 10.7 (0.3–30.2) COI and 17.2 U/mL (2.8–31.0) after the first, while 12.2 (2.8–37.9) COI and 24.6 U/mL (8.4–126.1) after the second dose of CP therapy, respectively. A weak negative correlation was observed between the anti-SARS-CoV-2 nucleocapsid-specific total Ig level after the second transfusion and the time from transfusion to discharge (R² = 0.312, F = 6.8, p = 0.02) (data not shown). Interestingly, other post-transfusion anti-SARS-CoV-2 Ig levels did not affect the time interval from CP therapy to oxygen weaning, discharge, or PCR positivity. We experienced a gradual decrease in antibody consumption in our patients receiving multiple CP transfusions that was strongly correlated and concurrent with clinical and radiological improvement (Fig. 3).

Finally, no COVID-19-related death was recorded. One patient died as a result of lymphoma progression. He received remdesivir and CP consecutively and was asymptomatic for COVID-19 at death with a persistent SARS-CoV-2 PCR positivity. No transfusion-related adverse events were observed during or after CP therapy.

**Discussion**

Several groups have recently reported a protracted disease course of COVID-19 in B-cell-depleted patients [16–21]. A common phenomenon was a transient improvement during
antiviral therapy and a rapid relapse after the conclusion of treatment. Also, a recurrent experience was a sustained improvement following CP therapy, occasionally with cessation of oxygen dependency within days. As we have had similar experiences in our own patient population with remdesivir monotherapy, we hypothesized that inhibition of viral replication in the absence of an effective humoral immune response was not sufficient for recovery from COVID-19. As part of the humoral immune response, antibodies produced by B-cells are essential for antibody-driven virus elimination. Also, accumulating evidence suggested that specific T-cell responses are unable to control SARS-CoV-2 viral infection in the absence of humoral immunity and neutralizing antibodies [1, 6, 22]. These observations led to the

![Fig. 1](https://example.com/fig1.png)

**Fig. 1** The effect of clinical parameters and timing of convalescent plasma therapy on outcome. Anti-CD20 therapy prior to COVID-19 diagnosis was associated with a prolonged PCR positivity (a). Subjects receiving remdesivir and CP (REM+CPT) simultaneously were discharged earlier compared to patients treated consecutively (b). Simultaneously treated patients showed a remarkably reduced time interval to PCR negativity (c), loss of oxygen demand from diagnosis (d), while there was no difference in the length of oxygen therapy after initiation of CP therapy (e). Early CP administration led to an early cessation of oxygen demand, compared to patients receiving CP at least 10 days after COVID-19 diagnosis (f). Comparisons were performed using Mann–Whitney U-test or t-test. PCR polymerase chain reaction, dg. diagnosis, REM remdesivir, CPT convalescent plasma therapy, O2 oxygen.
administration of remdesivir in combination with CP in such patient cohorts.

This study reports the clinical benefit of the combination of remdesivir and CP therapy in 20 consecutive patients with COVID-19 disease and B-cell lymphopenia, considered as a consequence of either the underlying disease or the treatment given for it. While COVID-19-specific antiviral treatments can induce a transient decrease in symptoms, they fail to produce a complete viral clearance and sustained clinical improvement in this patient population. In our series, former treatment with anti-CD20 monoclonal antibodies was associated with prolonged SARS-CoV-2 PCR positivity, which can be attributed to the extended and profound B-cell depletion caused by the compound with an elevated risk of protracted viral shedding and within-host viral evolution (Online Resource 2) [23]. Also, achievement of early SARS-CoV-2 PCR negativity, and thus avoiding delay in treatment, is of particular importance for patients who acquired COVID-19 in the setting of a progressing HM [24].

For the same reason, the rapid and sustained improvement in the clinical condition of immunocompromised hematological patients is of paramount importance. Our results provide a clear evidence that this population can benefit from early and combined administration of remdesivir and CP. Concomitant use showed benefits regarding hospital stay, length of oxygen dependency, and time needed for PCR negativity suggesting early treatment initiation as the most important aspect. The fact that there was no difference in the length of oxygen demand after plasma administration between patients receiving remdesivir and CP treatment at the same time and those receiving it separately implies that passively transferred antibodies play a key role in COVID-19 clinical recovery. The overall clinical improvement observed after CP therapy correlated strongly with early administration, as demonstrated by the rapid decrease in oxygen demand and length of hospital stay. The decreasing effectiveness of plasma therapy late in the course of the disease or even after remdesivir therapy has been also emphasized by a recent large-scale study [25]. Our observation is consistent with previously published reports regarding the discrepancy between the time needed for clinical recovery and PCR negativity. In the face of the rapidity of clinical response, time to viral clearance after passive immunotherapy is highly variable in B-cell-depleted patients [8].

As Gharbharan et al. reported, the peak and duration of immediate seropositivity after CP transfusion varied substantially [26]. We assume that this phenomenon may be the result of the individual consumption rate of SARS-CoV-2 IgG
depending on the extent and severity of COVID-19. We experienced a gradual decrease in antibody consumption in our patients receiving multiple CP transfusions that strongly correlated with clinical and radiological improvement. Also, while the specificities of the Hungarian blood banking system and the paucity of available supply sometimes resulted in a delay of CP transfusion, we were able to utilize this observation, and tailor CP therapy to the rate of decline in anti-SARS-CoV-2 Ig titers [27]. With subsequent CP transfusions, we aimed to achieve the rate of decline observed in the immunocompetent patient population with moderate-severe COVID-19 disease and experienced a spectacular clinical improvement when this rate was approached [28]. Importantly, we did not allow SARS-CoV-2 Ig levels to fall below any of their cut-off values. The strength of our strategy is supported by observations that post-infection elimination of SARS-CoV-2 IgG predisposes patients to early relapse [16, 29]. Unlike Rodionov et al., we cannot report on a strong correlation between anti-SARS-CoV IgG titers and improvement in clinical status [30]. While the WHO Clinical Progression Scale was not monitored on a daily basis, we considered cessation of oxygen demand and discharge from hospital to be strong indicators of clinical improvement. In summary, our data suggest that the rate and magnitude of clinical improvement are in relation to maintenance of Ig levels above the cut-off levels, preventing rapid decline through repeated CP transfusions.

Hyperimmune intravenous immunoglobulins derived from plasma and monoclonal antibodies against the structural proteins of SARS-CoV-2 are tempting treatment options in B-cell-depleted patients with COVID-19 but face permanent competition from CP. The amount of plasma needed to produce a single dose of hyperimmune globulin raises ethical concerns during a pandemic. Specific monoclonal antibodies are recommended both for non-hospitalized patients with mild to moderate COVID-19 who are at high risk of developing severe illness, including those immunocompromised due to age, medical conditions, or immunosuppressive medications, and for hospitalized patients with moderate to severe disease (not requiring high-flow oxygen, non-invasive, or mechanical ventilation) and negative SARS-CoV-2 anti-spike IgG. However, the antibodies developed
may lose effectiveness when a new mutant becomes dominant, and the safety and efficacy of combining them with remdesivir are unknown. With the rapid emergence of SARS-CoV-2 variants, therapeutic gaps may be needed to be filled while production and deployment of refined monoclonal antibodies occur. In this context, CP treatment will certainly be inevitable until the global pandemic is over.

Effective patient education may be the reason why patients were admitted with early symptoms and mostly mild-to-moderate COVID-19 severity. This may have contributed to our excellent survival rate, which is far superior to the data described in multicenter analyses [2, 13, 31]. Our therapeutic approach also appears to be effective during pregnancy with no evidence of fetal distress [32, 33].

We acknowledge the limitations of this non-randomized study without control group comparisons. However, in our opinion, real-world data is of particular importance in patient populations with unusual disease settings and thus limited possibilities for performing a sufficiently powered randomized control trial. To adequately attribute any outcome to the combination of remdesivir and CP therapy, further information needs to be acquired in this clinical setting.

In conclusion, we reported the outcomes of 20 B-cell depleted patients with HMs and COVID-19 infection. Our results support the assumption that the early combination of antiviral therapy and passive immunotherapy facilitates clinical recovery from COVID-19 and viral clearance of SARS-CoV-2. Passive transfer of COVID-19-specific neutralizing antibodies with CP therapy was effective and safe in a patient population with compromised immune systems, irrespective of the cause resulting in B-cell lymphopenia.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00277-022-04924-6.

Author contribution F.M., L.P., and B.N.Jr. designed the study, analyzed the data, and wrote the initial draft of the manuscript. E.P., K.F., and Á.I. contributed to the project design and data analysis. Sz., U., A.D., M.S., Zs.S., G.N., and Zs.H. collected the data. All the authors read and approved the final version of the manuscript.

Funding Open access funding provided by University of Debrecen.

Availability of data and materials The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Code availability Not applicable.

Declarations

Ethics approval The study was approved by the Scientific and Research Ethics Committee of the University of Debrecen and the Ministry of Human Capacities under the registration number of 32568–3/2020/EÜIG. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.

Consent to participate Informed consent was obtained from all individual participants included in the study.

Consent for publication Not applicable.

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Hueso T, Pouderoux C, Pére H et al (2020) Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19, Blood 136:2290–2295. https://doi.org/10.1182/BLOOD.2020008423
2. Pagano L, Salamanter-García J, Marchesi F et al (2021) COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVID-DEHA). J Hematol Oncol 14:168. https://doi.org/10.1186/s13045-021-01177-0
3. Dülery R, Lamure S, Delord M et al (2021) Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol 96:934–944. https://doi.org/10.1002/ AJH.26209
4. Sacco KA, Abraham RS (2018) Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution. Immunotherapy 10:713–728. https://doi.org/10.2217/IMT-2017-0178
5. Beigel JH, Tomashek KM, Dodd LE et al (2020) Remdesivir for the treatment of COVID-19 — Final Report. N Engl J Med 383:1813–1826. https://doi.org/10.1056/nejmoa2007764
6. Buckland MS, Galloway JB, Phogartaigh CN et al (2020) Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nat Commun 11:6385. https://doi.org/10.1038/s41467-020-19761-2
7. Tepasse PR, Hafezi W, Lutz M et al (2020) Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. Br J Haematol 190:185–188. https://doi.org/10.1111/bjh.16896
8. Gaitzsch E, Passerini V, Khathazas E et al (2021) COVID-19 in patients receiving CD20-depleting immunochemotherapy for B-cell lymphoma. HemaSphere 5:e603. https://doi.org/10.1097/HS9.0000000000000603
9. Abani O, Abbas A, Abbas F et al (2021) Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet 397:2049–2059. https://doi.org/10.1016/S0140-6736(21)00897-7
10. Cheng Y, Wong R, Soo YOY et al (2005) Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 24:44–46. https://doi.org/10.1007/ S10096-004-1271-9
11. Ko JH, Seok H, Cho SY et al (2018) Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus
infection: a single centre experience. Antivir Ther 23:617–622. https://doi.org/10.3851/IMP3243
12. Simonovitch VA, Burgos Pratx LD, Scibona P et al (2021) A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med 384:619–629. https://doi.org/10.1056/NEJMoa2031304
13. Thompson MA, Henderson JP, Shah PK et al (2021) Association of convalescent plasma therapy with survival in patients with hematologic cancers and Covid-19. JAMA Oncol 7:1167–1175. https://doi.org/10.1001/JAMAONCOL.2021.1799
14. Hueo T, Godron A-S, Lanoy E et al (2022) Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and Covid-19: a longitudinal cohort and propensity score analysis. Leukemia 36:1025–1034. https://doi.org/10.1038/s41375-022-01511-6
15. Marshall JC, Murthy S, Diaz J et al (2020) A minimal common outcome measure set for Covid-19 clinical research. Lancet Infect Dis 20:e192–e197. https://doi.org/10.1016/S1473-3099(20)30483-7
16. Lancman G, Mascarénhas J, Bar-Natan M (2020) Severe Covid-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia. J Hematol Oncol 13:131. https://doi.org/10.1186/s13045-020-00968-1
17. Clark E, Guilpain P, Filip IL et al (2020) Convalescent plasma for persisting Covid-19 following therapeutic lymphocyte depletion: a report of rapid recovery. Br J Haematol 190:e154–e156. https://doi.org/10.1111/bjh.16981
18. Kenig A, Ishay Y, Kharouf F, Rubin L (2021) Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products. Clin Immunol 227:108723. https://doi.org/10.1016/j.clim.2021.108723
19. Furlan A, Forner G, Cipriani L et al (2021) Dramatic response to convalescent hyperimmune plasma in association with an extended course of remdesivir in 4 B cell–depleted non-Hodgkin lymphoma patients with SARS-CoV-2 pneumonia After Rituximab Therapy. Clin Lymphoma Myeloma Leuk 21:e731–e735. https://doi.org/10.1016/j.clml.2021.05.013
20. Ferrari S, Capriolo C, Weber A et al (2021) Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies. Leuk Lymphoma 62:1400–1496. https://doi.org/10.1080/10428194.2021.1872070
21. Casarola G, D’Abbondanza M, Curcio R et al (2021) Efficacy of convalescent plasma therapy in immunocompromised patients with Covid-19: a case report. Clin Infect Pract 12:100096. https://doi.org/10.1016/j.cipr.2021.100096
22. Maly J, Veletzky L, Heide J et al (2021) Sustained response after remdesivir and convalescent plasma therapy in a B-cell–depleted patient with protracted coronavirus disease 2019 (COVID-19). Clin Infect Dis 73:e4020–e4024. https://doi.org/10.1093/cid/ciaa1637
23. Nussenblatt V, Roder AE, Das S et al (2021) Year-long COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with B cell depletion. J Infect Dis:jia622. https://doi.org/10.1093/INFDIS/JIA622
24. Weinbergerova B, Mayer J, Kabut T et al (2021) Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients. Hematol Oncol 39:715–720. https://doi.org/10.1002/HON.2908
25. Koirala J, Gyanwali P, Gerzoff RB et al (2021) Experience of Treating Covid-19 with remdesivir and convalescent plasma in a resource-limited setting: a prospective, observational study. Open Forum Infect Dis 8:ofab391. https://doi.org/10.1093/OFID/OFAB391
26. Gharbharan A, Geurts van Kessel CH, Jordans CCE et al (2021) Effects of treatment of coronavirus disease 2019 with convalescent plasma in 25 B-cell–depleted patients. Clin Infect Dis:ciab647. https://doi.org/10.1093/CID/CIAB647
27. Tordai A, Nagy S, Baróti-Tóth K et al (2021) Effect of the SARS-CoV2 pandemic in Hungarian blood banking. Hematologia–Transfuziology 53:96–105. https://doi.org/10.1556/2068.2020.53.2.6
28. Ibarrondo FJ, Fulcher JA, Goodman-Meza D et al (2020) Rapid decay of anti–SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med 383:1085–1087. https://doi.org/10.1056/NEJMc2025179
29. Schenker C, Hirzel C, Walti LN et al (2021) Convalescent plasma and remdesivir for protracted COVID-19 in a patient with chronic lymphocytic leukaemia: a case report of late relapse after rapid initial response. Br J Haematol. https://doi.org/10.1111/bjh.17806
30. Rodionov RN, Biener A, Spiegh P et al (2021) Potential benefit of convalescent plasma transfusions in immunocompromised patients with Covid-19. Lancet Microbe 2:e138. https://doi.org/10.1016/S2666-5247(21)00030-6
31. Vijenthira A, Gong IY, Fox TA et al (2020) Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood 136;2881–2892. https://doi.org/10.1182/BLOOD.2020008824
32. Anderson J, Schauer J, Bryant S, Graves CR (2020) The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: a case report. Case Rep Womens Health 27:e00221. https://doi.org/10.1016/j.crwh.2020.e00221
33. Ahmed E, Dina E, Usman A (2021) The effect of remdesivir and convalescent plasma in severe COVID-19 in pregnancy. Clin Med Rev Case Rep 8:349. https://doi.org/10.23937/2378-3636/1410349

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

**Ferenc Magyari**1,2 · László Imre Pinczés1,2 · Edit Páayer1,2 · Katalin Farkas1,2 · Szilvia Ujfaluusi3 · Ágnes Diószegi3 · Máté Sik4 · Zsófia Simon1 · Gergely Nagy5 · Zsuzsanna Hevesy6 · Béla Nagy Jr6 · Árpád Illés1,2

1 Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
2 Doctoral School of Clinical Medicine, University of Debrecen, Debrecen, Hungary
3 Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
4 Department of Radiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
5 Department of Emergency Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
6 Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary